ZFAT

Across TCGA pan-cancer cohorts, ZFAT RNA differs between tumor and matched normal tissue in 12 of 18 cancer types tested, making tumor–normal expression one of ZFAT’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where ZFAT RNA is more highly expressed in tumor relative to normal tissue. In most cancer types ZFAT is over-expressed in tumor, although a few such as KIRP and KICH show the opposite, repressed pattern.

LIHC, KIRP, and HNSC are the cancer types where ZFAT tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ZFAT RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Male	II,III,IV	+1.040	<.001	9	view →
KIRP	Male	All	−1.009	<.001	7	view →
HNSC	Female	All	+0.620	<.001	7	view →
KICH	Female	All	−0.896	<.001	6	view →
LUAD	Male	All	+0.370	<.001	6	view →
CHOL	All	All	+1.721	<.001	5	view →
STAD	Male	II,III,IV	+0.603	.004	5	view →
COAD	All	IV	+0.488	.004	4	view →
BLCA	All	All	+0.386	.014	4	view →
LUSC	All	All	+0.302	<.001	4	view →
BRCA	All	II,III,IV	+0.221	<.001	4	view →
PRAD	All	All	+0.249	.002	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 12 lineages.

ZFAT–LIHC

Open the LIHC breakdown →